New hope for tough-to-treat hodgkin lymphoma patients
NCT ID NCT02227199
Summary
This study tested a combination of a targeted cancer drug (brentuximab vedotin) with three chemotherapy drugs for patients whose Hodgkin lymphoma returned or didn't respond to previous treatment. The trial aimed to find the safest dose and see how well this combination worked to control the cancer. Researchers enrolled 45 patients to determine if this approach could help prepare patients for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.